A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

Maxim Kebenko, Marie Elisabeth Goebeler, Martin Wolf, Annette Hasenburg, Ruth Seggewiss-Bernhardt, Barbara Ritter, Beate Rautenberg, Djordje Atanackovic, Andrea Kratzer, James B. Rottman, Matthias Friedrich, Eva Vieser, Stefanie Elm, Ingrid Patzak, Dorothea Wessiepe, Sabine Stienen, Walter Fiedler*

*Corresponding author for this work
41 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors'. Together they form a unique fingerprint.

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science